Householder Group Estate & Retirement Specialist LLC Lowers Position in Novo Nordisk A/S (NYSE:NVO)

Householder Group Estate & Retirement Specialist LLC trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 15.7% during the 4th quarter, Holdings Channel reports. The fund owned 3,341 shares of the company’s stock after selling 623 shares during the period. Householder Group Estate & Retirement Specialist LLC’s holdings in Novo Nordisk A/S were worth $287,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Natixis Advisors LLC boosted its stake in shares of Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares in the last quarter. Norman Fields Gottscho Capital Management LLC boosted its position in Novo Nordisk A/S by 45.3% during the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after acquiring an additional 19,870 shares in the last quarter. Talbot Financial LLC purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $4,066,000. Versant Capital Management Inc purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $86,000. Finally, Zions Bancorporation N.A. raised its position in shares of Novo Nordisk A/S by 57.0% in the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after acquiring an additional 6,726 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on NVO. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S has an average rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $78.74 on Friday. The company has a 50 day moving average price of $98.33 and a 200 day moving average price of $117.69. The firm has a market capitalization of $353.33 billion, a P/E ratio of 25.48, a PEG ratio of 0.92 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.